2007 to 2023 Saw Decline in Menopausal Hormone Therapy Usage Rates
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, Sept. 10, 2024 -- Menopausal hormone therapy (HT) usage rates declined from 2007 to 2023 and remain low, according to a study presented at the annual meeting of The Menopause Society, held from Sept. 10 to 14 in Chicago.
Mariam Saadedine, M.D., from the Mayo Clinic in Jacksonville, Florida, and colleagues described systemic menopausal HT utilization in women aged 40 years and older between 2007 and 2023 using claims data from the OptumLabs data warehouse. The annual rate of HT utilization was defined as the proportion of women with at least 180 days of a filled prescription for systemic estrogen-containing menopausal HT within one year.
The study population increased from about 2 million in 2007 to 4.5 million in 2023. The researchers found that among women aged 40 years or older, HT use was 4.6 percent in 2007, decreased to 2.5 percent between 2007 and 2014, and continued decreasing, reaching 1.8 percent in 2023. The most common route of administration was oral. HT use decreased from 3.2, 6, and 7.3 percent in 2007 to 1.5, 3.6, and 3.8 percent in 2023 among women aged 45 to 49, 50 to 54, and 55 to 59 years.
"These findings suggest that substantial barriers to HT use remain, and additional efforts are needed to educate women and clinicians about menopause management and HT use more specifically," coauthor Stephanie Faubion, M.D., medical director of The Menopause Society, said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-09-11 09:39
Read more
- Ozempic, Wegovy Might Help Lower Alzheimer's Risk in People With Diabetes
- Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
- In Utero Exposure to COVID-19 Not Tied to Later Neurodevelopmental Issues
- Work-Related Stress Linked to Lower Odds of Average, Optimal Heart Health
- Global TB Cases Hit Record High, TB Becomes Top Infectious Disease Killer
- Obesity Could Cause 40% of Hormone-Positive Breast Cancers in Older Women
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions